Navigation Links
Former Head of UK Medicines & Healthcare Products Regulatory Agency (MHRA) Sir Alasdair Breckenridge Joins NDA Partners

Madison, VA (PRWEB) August 14, 2013

Carl Peck, MD, Chairman of NDA Partners LLC (NDAP), today announced that Sir Alasdair Breckenridge, former head of the UK Medicines & Healthcare Products Regulatory Agency (MHRA) has joined NDA Partners as a partner in the firm. MHRA is the Department of Health agency responsible for regulating all medicines and medical devices marketed in the UK.

In his role at NDA Partners, Sir Alasdair will provide leadership for the firm’s expanding EU operations and expert consulting to its worldwide client base in complex and rapidly evolving topics such as health care policy, health technology assessment, reimbursements, EU clinical trials, global product development, global regulatory strategies, benefit-risk assessment, and bioethics. “Alasdair’s decades of experience at the forefront of drug development science and deep understanding of the global regulatory environment will be a tremendous asset for our clients as they seek the best available advice to guide their development programs”, said Dr Peck. “We look forward to Alasdair’s active involvement on our team and with our global client base”.

Sir Alasdair has a long and prestigious career in drug development science and regulatory affairs. He was the first Chair of MHRA when it was formed in 2003 and retained this position until his retirement from the Agency in 2012. During his tenure at MHRA, he served as the first Chair of the Department of Health's Emerging Science and Bioethics Advisory Committee (ESBAC), an organization responsible for providing advice to UK health departments on emerging healthcare scientific developments and their ethical, legal, social and economic implications. He was a member of the Medical Research Council, worked closely on several programs of the European Union, the World Health Organization and the International Union of Pharmacology, and was Chair of the Committee on Safety of Medicines. Prior to MHRA, he was Professor of Clinical Pharmacology at the University of Liverpool and a member and then Chairman of local and regional health authorities in the north-west of England, including Chairman of the North West Regional Office. Sir Alasdair is a clinical pharmacologist and after training at the Royal Postgraduate Medical School, he was appointed to the Chair of Clinical Pharmacology at the University of Liverpool. Sir Alasdair was knighted in 2004.

Read the full story at

Source: PRWeb
Copyright©2012 Vocus, Inc.
All rights reserved

Related biology technology :

1. Fox Insurance Company Awarded $3.3 Million in Arbitration Against Former Pharmacy Benefit Manager
2. Former Sanofi-aventis and US Oncology Executive Joins New Century Health as Chief Executive Officer
3. PAREXEL Appoints Former Senior FDA Official David Elder to Global Team of Strategic Compliance Experts
4. PharmaVentures Helps Secure Investor for Former MSD Research Site
5. Dr. Michael Yaremchuk, Leading Performer of Custom-Designed Facial Implants, Pioneers Bespoke Plastic Surgery
6. Former FDA Inspectors Train Medical Device, Pharmaceutical Companies How to Prepare for FDA Inspections of Their Quality Systems
7. Ceres Expands Board of Directors with former BP Chief Scientist and Undersecretary of Energy Steven Koonin
8. Former Stryker CEO Takes Reins at sBioMed
9. Lucas Bagnell Varga LLC Secures $17.4 Million Award For Former Applied Biosystems Executives
10. Non-Intrusive Black Mold Removal Procedure Released By Former Mold Remediation Specialist, Explains
11. Delta Point Strengthens Management and Expands Consultancy Services with Addition of Former AstraZeneca Executive Michael Hickey
Post Your Comments:
(Date:11/24/2015)... Florida (PRWEB) , ... November 24, 2015 , ... ... biggest event of the year and one of the premier annual events for ... and ran from 8–11 November 2015, where ISPE hosted the largest number of ...
(Date:11/24/2015)... India , November 24, 2015 ... a new market research report "Oligonucleotide Synthesis Market by ... Application (PCR, Gene Synthesis, Diagnostic, DNA, RNAi), End-User (Research, ... 2020", published by MarketsandMarkets, the market is expected to ... Million in 2015, at a CAGR of 10.1% during ...
(Date:11/24/2015)... 24, 2015 SHPG ) announced today that ... Piper Jaffray 27 th Annual Healthcare Conference in ... at 8:30 a.m. EST (1:30 p.m. GMT). --> SHPG ... will participate in the Piper Jaffray 27 th Annual Healthcare ... Tuesday, December 1, 2015, at 8:30 a.m. EST (1:30 p.m. GMT). ...
(Date:11/24/2015)... QUEBEC CITY , Nov. 24, 2015 /PRNewswire/ ... (the "Company") announced today that the remaining 11,000 ... Common Share Purchase Warrants (the "Series B Warrants") ... agreement were exercised on November 23, 2015, which ... Common Shares.  After giving effect to the issuance ...
Breaking Biology Technology:
(Date:10/29/2015)... , Oct. 29, 2015   MedNet Solutions , ... entire spectrum of clinical research, is pleased to announce ... Tech Association (MHTA) as one of only three finalists ... "Software – Small and Growing" category. The Tekne Awards honor ... have shown superior technology innovation and leadership. ...
(Date:10/29/2015)... RESTON, Va. , Oct. 29, 2015 ... announced today that it has released a new version ... Daon customers in North America ... gains. IdentityX v4.0 also includes a FIDO UAF ... customers are already preparing to activate FIDO features. These ...
(Date:10/29/2015)... BOSTON , Oct. 29, 2015  Connected health ... phenomena driving the explosion of technology-enabled health and wellness, ... his new book, The Internet of Healthy ... apps, sensors or smartphones even existed, Dr. Kvedar, vice ... model of health care delivery, moving care from the ...
Breaking Biology News(10 mins):